CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,882 | -20.7% | 468,055 | -2.2% | 0.00% | 0.0% |
| Q2 2023 | $16,239 | -36.8% | 478,574 | -32.9% | 0.00% | -50.0% |
| Q1 2023 | $25,675 | -30.8% | 713,562 | -14.3% | 0.00% | -33.3% |
| Q4 2022 | $37,127 | -99.8% | 833,009 | +11.7% | 0.01% | +100.0% |
| Q3 2022 | $20,972,000 | +45.8% | 746,008 | +39.9% | 0.00% | +50.0% |
| Q2 2022 | $14,381,000 | -60.0% | 533,402 | -49.4% | 0.00% | -50.0% |
| Q1 2022 | $35,910,000 | +1.5% | 1,054,325 | +15.2% | 0.00% | +33.3% |
| Q4 2021 | $35,379,000 | -25.4% | 915,608 | +4.2% | 0.00% | -25.0% |
| Q3 2021 | $47,425,000 | +264.5% | 878,409 | +125.8% | 0.00% | +300.0% |
| Q2 2021 | $13,010,000 | +90.1% | 389,048 | +17.1% | 0.00% | 0.0% |
| Q1 2021 | $6,844,000 | +33.3% | 332,230 | +13.4% | 0.00% | 0.0% |
| Q4 2020 | $5,135,000 | – | 293,068 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |